Neofect Valuation
Is A290660 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A290660 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate A290660's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A290660's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A290660?
Key metric: As A290660 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is A290660's PS Ratio? | |
|---|---|
| PS Ratio | 1.8x |
| Sales | ₩23.11b |
| Market Cap | ₩40.85b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | 1618.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does A290660's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.4x | ||
A241820 PCL | 5.1x | n/a | ₩39.9b |
A307280 Wonbiogen | 1.5x | n/a | ₩43.5b |
A115480 CU Medical Systems | 1x | n/a | ₩38.7b |
A405000 Plasmapp | 2.1x | n/a | ₩31.6b |
A290660 Neofect | 1.8x | n/a | ₩40.8b |
Price-To-Sales vs Peers: A290660 is good value based on its Price-To-Sales Ratio (1.8x) compared to the peer average (2.4x).
Price to Sales Ratio vs Industry
How does A290660's PS Ratio compare vs other companies in the KR Medical Equipment Industry?
Price-To-Sales vs Industry: A290660 is good value based on its Price-To-Sales Ratio (1.8x) compared to the KR Medical Equipment industry average (2.1x).
Price to Sales Ratio vs Fair Ratio
What is A290660's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.8x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate A290660's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Access Bio
₩188.3b
Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.
A950130
₩5,570.00
7D
2.0%
1Y
-37.1%
Wonbiogen
₩43.5b
Develops and sells medical equipment in South Korea.
A307280
₩1,225.00
7D
-1.1%
1Y
-21.6%
Boditech Med
₩346.3b
Offers instruments and diagnostic reagents in South Korea and internationally.
A206640
₩15,760.00
7D
-2.1%
1Y
-12.9%